A failure in breast cancer and now a delay for Polivy? Roche can't catch a break
Despite a sales boost last quarter, CEO Severin Schwan noted several setbacks in a presentation for investors on Monday, including a delay in the pharma giant’s mission to bring its diffuse large B-cell lymphoma (DLBCL) drug Polivy to the first line.
Eight months after teasing some positive topline results in previously untreated patients, Roche has yet to file for an approval because the FDA has requested to see more data on progression-free survival, according to Bill Anderson, CEO of Roche Pharmaceuticals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.